Jazz Pharmaceuticals (JAZZ) Revenue & Earnings 2020-2026

Revenue, EBITDA, operating income, net income, EPS, and shares

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares across quarters

TTM Revenue: $4.44B
Q. Revenue: $1.07B
TTM EBITDA: $675.08M
TTM Op. Income: $-37.75M
Q. Op. Income: $336.60M
TTM Net Income: $29.49M
Q. Net Income: $293.10M
EPS: $4.73
Shares Out.: $61.90M

$4.44B in TTM revenue grew 9.2% YoY, reaching $1.07B last quarter. TTM EBITDA of $675.08M and TTM operating income of $-37.75M shows growth is flowing through. Net income of $29.49M TTM confirms the company is converting revenue into profit. Revenue is growing at a healthy pace — a signal to hold.

TTM Revenue

Reveals whether the core business is growing or shrinking

Quarterly Revenue

Highlights seasonal patterns and short-term momentum

TTM EBITDA

Shows if underlying operating profitability is improving

Quarterly EBITDA

Tracks near-term operating profitability trends

TTM Operating Income

Smoothed operating profit over the past four quarters

Quarterly Operating Income

Profit from core operations before financing costs

TTM Net Income

The bottom line — is the company making more money?

Quarterly Net Income

Short-term profit after all expenses and taxes

EPS

Earnings per share — profit attributable to each share

Shares Outstanding

Declining means buybacks benefit remaining holders